Navigation Links
New research may show why some prostate cancer recurs after treatment
Date:10/11/2007

Lake Tahoe, CA, October 11, 2007 Cancer researchers have long worked to understand why some prostate cancers recur after the use of therapies designed to stop the production of testosterone and other androgens that fuel cancer cell growth. New research has now detected that androgen-synthesizing proteins are present within cancer cells, which suggests that cancer cells may develop the capacity to produce their own androgens.

The presence of these proteins may explain why some prostate cancers become resistant to these widely-used therapies, and offers new directions for research into future treatments that could block the development of androgens in the cancer cells. The study, funded by the Prostate Cancer Foundation and the National Cancer Institute, was presented today at the Foundations annual Scientific Retreat.

Androgen-deprivation therapy is routinely used in the treatment of advanced (metastatic) prostate cancer, in order to deprive cancer cells of these hormones that fuel their growth. However, over time cancer cells can become androgen independent, and grow even in the presence of these medications. This type of the cancer is a lethal form of the disease, with most patients dying 18 to 24 months after becoming resistant to hormone suppression. Research in the field has focused on understanding the mechanisms used by these cancer cells to become castration resistant.

Investigators Peter Nelson, M.D., Elahe Mostaghel, M.D., Ph.D., and Bruce Montgomery, M.D. from the Fred Hutchinson Cancer Research Center and University of Washington, conducted tests on tumors removed and preserved from deceased prostate cancer patients during rapid autopsies immediately after death. All the patients had received androgen-blocking therapies during the course of treatment to suppress tumor growth.

The researchers were able to detect in the tumors the key proteins, or enzymes, needed for a cell to produce its own testosterone from
'/>"/>

Contact: Sharon Reis
prostate@gymr.com
202-745-5100
GYMR
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Kidney Stones - Interesting New Research implicates bacteria as its cause
2. Stem cell research- now Nobel Laureates join the debate
3. Researchers urge caution in using ear tube surgery
4. Paracetamol May Cause Live Damage Warns Consumer Education and Research Centre
5. Spouses and other partners lower blood pressure says new research
6. Researchers Scale to assess the Severity of Epilepsy in Kids
7. More Research Required For COPD
8. Researchers identify the early makers of Neonatal Sepsis
9. OHSU Researchers Announce New Discovery
10. Skin Cancer Research To Go Global
11. Researchers Identify Gene Connected To Bipolar Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 2Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 3Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 4Health News:MediVoice(R) Partners With VisionTree(R) to Integrate Its Voice-Activated e-Prescribing Solution Into VisionTree's VTOC(TM) Web-Based Patient Management System 2Health News:MediVoice(R) Partners With VisionTree(R) to Integrate Its Voice-Activated e-Prescribing Solution Into VisionTree's VTOC(TM) Web-Based Patient Management System 3Health News:Cardiome Announces Preferred Share Financing 2Health News:Cardiome Announces Preferred Share Financing 3Health News:Study suggests human visual system could make powerful computer 2Health News:Study suggests human visual system could make powerful computer 3Health News:$15 Million Donation From The Karabots Foundation Enables The Children's Hospital of Philadelphia to Open a New Pediatric Care Facility in Norristown, Pennsylvania 2Health News:$15 Million Donation From The Karabots Foundation Enables The Children's Hospital of Philadelphia to Open a New Pediatric Care Facility in Norristown, Pennsylvania 3Health News:Rock The Cradle's Bad Boy Landon Brown Owes His Irresistible New Smile to Dr. Michael Kosdon 2
Breaking Medicine Technology:Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 2Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 3Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 4Perceptive Informatics Introduces Greater Convergence Between EDC and RTSM Solutions in Its eClinical Suite 5TOPAZ Technologies Introduces Biosafety Software Solution 48428 1TOPAZ Technologies Introduces Biosafety Software Solution 48428 2TOPAZ Technologies Introduces Biosafety Software Solution 48428 3As Sleep Improves Grades Seem to Go Up 48427 1As Sleep Improves Grades Seem to Go Up 48427 2MDS Nordion Begins to Manufacture Cardiac Imaging Agent 48425 1MDS Nordion Begins to Manufacture Cardiac Imaging Agent 48425 2MDS Nordion Begins to Manufacture Cardiac Imaging Agent 48425 3